Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Study supports multigene panel testing for all breast cancer patients with second primary cancers

Key clinical point: All patients with breast cancer who develop a second primary cancer should undergo multigene panel testing, according to researchers.

Major finding: Mutation rates in BRCA1/2-negative breast cancer patients with multiple primary cancers were approximately 7% to 9%, compared with about 4% to 5% in BRCA1/2-negative patients with a single breast cancer.

Study details: A comparison of mutation rates in 1,000 high-risk breast cancer patients (551 with multiple primary cancers and 449 with a single breast cancer) and 1,804 familial breast cancer patients (340 with multiple primaries and 1,464 with a single breast cancer).

Disclosures: This research was supported by grants from government agencies and foundations as well as the University of Pennsylvania. Some authors disclosed relationships with a range of companies.